Used in bioconjugation and pharmaceutical research as a hydrophilic linker to improve solubility and pharmacokinetics of drug molecules. Its PEG-based structure enhances biocompatibility and reduces immunogenicity in therapeutic compounds. Commonly employed in the synthesis of antibody-drug conjugates (ADCs) and targeted delivery systems due to its stability and ease of functionalization. The methyl acetate end group allows for selective reactions with nucleophiles, enabling controlled attachment to payloads or targeting moieties. Also applied in PEGylation strategies to prolong circulation time of peptides and small molecules.